WO2011126342A3 - Utilisation inédite d'un extrait de polygonatum falcatum ou de polygonatum sibiricum - Google Patents

Utilisation inédite d'un extrait de polygonatum falcatum ou de polygonatum sibiricum Download PDF

Info

Publication number
WO2011126342A3
WO2011126342A3 PCT/KR2011/002491 KR2011002491W WO2011126342A3 WO 2011126342 A3 WO2011126342 A3 WO 2011126342A3 KR 2011002491 W KR2011002491 W KR 2011002491W WO 2011126342 A3 WO2011126342 A3 WO 2011126342A3
Authority
WO
WIPO (PCT)
Prior art keywords
polygonatum
obesity
falcatum
metabolic syndrome
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/002491
Other languages
English (en)
Korean (ko)
Other versions
WO2011126342A2 (fr
Inventor
권혁상
고종희
유종수
윤종민
장현수
연승우
강재훈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ildong Pharmaceutical Co Ltd
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Priority to CN2011800175142A priority Critical patent/CN102844042A/zh
Priority to JP2013503700A priority patent/JP5799082B2/ja
Publication of WO2011126342A2 publication Critical patent/WO2011126342A2/fr
Publication of WO2011126342A3 publication Critical patent/WO2011126342A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une utilisation inédite d'un extrait de Polygonatum falcatum ou de Polygonatum sibiricum à des fins de prévention et de traitement de l'obésité ou du syndrome métabolique, et plus précisément, une composition pharmaceutique ou alimentaire contenant un extrait de Polygonatum falcatum ou de Polygonatum sibiricum à des fins de prévention et de traitement de l'obésité, des complications de l'obésité ou du syndrome métabolique. L'invention concerne également une utilisation inédite d'un extrait de Polygonatum falcatum ou de Polygonatum sibiricum en vue de la préparation d'un médicament destiné à prévenir et à traiter l'obésité, les complications de l'obésité ou le syndrome métabolique, ainsi qu'une méthode de traitement de l'obésité, des complications de l'obésité ou du syndrome métabolique au moyen dudit extrait. L'extrait de Polygonatum falcatum ou de Polygonatum sibiricum inhibe la différentiation des adipocytes et maintient un niveau élevé de SIRT1, ce qui entraîne une baisse de poids, une diminution de la graisse abdominale et une réduction de la tolérance au glucose, et ce qui peut donc être utilement utilisé pour prévenir et traiter l'obésité, les complications de l'obésité ou le syndrome métabolique.
PCT/KR2011/002491 2010-04-09 2011-04-08 Utilisation inédite d'un extrait de polygonatum falcatum ou de polygonatum sibiricum Ceased WO2011126342A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2011800175142A CN102844042A (zh) 2010-04-09 2011-04-08 镰刀黄精或狭叶黄精提取物的新用途
JP2013503700A JP5799082B2 (ja) 2010-04-09 2011-04-08 眞黄精又は黄精抽出物の新規な用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100032921 2010-04-09
KR10-2010-0032921 2010-04-09
KR1020100095987A KR101018531B1 (ko) 2010-04-09 2010-10-01 대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물
KR10-2010-0095987 2010-10-01

Publications (2)

Publication Number Publication Date
WO2011126342A2 WO2011126342A2 (fr) 2011-10-13
WO2011126342A3 true WO2011126342A3 (fr) 2012-03-08

Family

ID=43938249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002491 Ceased WO2011126342A2 (fr) 2010-04-09 2011-04-08 Utilisation inédite d'un extrait de polygonatum falcatum ou de polygonatum sibiricum

Country Status (4)

Country Link
JP (1) JP5799082B2 (fr)
KR (1) KR101018531B1 (fr)
CN (1) CN102844042A (fr)
WO (1) WO2011126342A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134125B2 (ja) * 2011-11-18 2017-05-24 株式会社紀文食品 逆転写酵素阻害剤およびキット
CN104324228B (zh) * 2014-11-26 2017-09-29 安徽省旌德博仕达农业科技有限公司 一种黄精含片及其制备方法
CN110537467A (zh) * 2019-09-25 2019-12-06 贵州百灵企业集团制药股份有限公司 一种滇黄精种子大棚育苗方法
JPWO2022075059A1 (fr) * 2020-10-07 2022-04-14
CN112870305A (zh) * 2021-02-26 2021-06-01 云南彝风堂医疗科技有限公司 一种治疗痛风的药物组合物、制剂及其制备方法和应用
CN115707782A (zh) * 2022-08-10 2023-02-21 贵州省植物园（贵州省园林科学研究所、贵州省植物研究所） 多花黄精致病真菌筛选方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020030687A (ko) * 2000-10-19 2002-04-25 신동수 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물
KR20020033336A (ko) * 2000-10-30 2002-05-06 박선민 둥굴레 뿌리 추출물을 함유하는 식품 조성물
KR20070059395A (ko) * 2005-12-06 2007-06-12 대구한의대학교산학협력단 황정 추출물을 유효성분으로 포함하는 면역증강용약학조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241293A (ja) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd メイラード反応阻害剤
CN1939475A (zh) * 2006-09-21 2007-04-04 张志祥 枸杞葛根胶囊及其制备工艺
CN101352539A (zh) * 2008-09-05 2009-01-28 何进爱 一种治疗糖尿病的中药组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020030687A (ko) * 2000-10-19 2002-04-25 신동수 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물
KR20020033336A (ko) * 2000-10-30 2002-05-06 박선민 둥굴레 뿌리 추출물을 함유하는 식품 조성물
KR20070059395A (ko) * 2005-12-06 2007-06-12 대구한의대학교산학협력단 황정 추출물을 유효성분으로 포함하는 면역증강용약학조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONGBIN CHEN ET AL.: "Hypoglycemic effects of aqueous extract of Rhizoma Polygonati Odorati in mice and rats", JOURNAL OF ETHNOPHARMACOLOGY, vol. 74, 2001, pages 225 - 229 *
S. B. CHOI ET AL.: "The Effects of Water Extract ofPolygonatum Odoratum (Mill) Druce on Insulin Resistance in 90% Pancreatectomized Rats", JOURNAL OF FOOD SCIENCE, vol. 67, no. 6, 2002, pages 2375 - 2379 *

Also Published As

Publication number Publication date
KR101018531B1 (ko) 2011-03-11
WO2011126342A2 (fr) 2011-10-13
JP5799082B2 (ja) 2015-10-21
CN102844042A (zh) 2012-12-26
JP2013523810A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
WO2008143182A1 (fr) Composition contenant un polyphénol dérivé de la réglisse
WO2009152189A8 (fr) Composition de topiramate/phentermine à faible dose et ses procédés d'utilisation
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2012033792A3 (fr) Traitement de maladies
MX2012002343A (es) Agente contra la obesidad, alimento o bebida contra la obesidad, agente que mejora la tolerancia a la glucosa, y alimento o bebida para mejorar la tolerancia a la glucosa.
WO2018169282A3 (fr) Composition pharmaceutique contenant de l'atpif1 pour le traitement du diabète
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
WO2018093238A3 (fr) Composition comprenant en tant qu'ingrédient actif une souche présentant une excellente aptitude à produire de l'acide formique pour prévenir ou traiter l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2011162523A3 (fr) Composition pour prévenir ou traiter l'ostéoporose, contenant du ssangwhatang ou un produit fermenté par lactobacillus de celui-ci
WO2011019735A3 (fr) Compléments nutritionnels
BR112012013011A2 (pt) odt; composição de odt; método para a preparação de um tablete de odt multiparticulado, método para tratar ou prevenir náusea e vômito pós operatória ou náusea e vômito pós- alta por até 24 horas após a dosagem, método para tratar pu prevenir náusea por até 24 horas após a dosagem e método para tratar ou prevenir náusea e vômito associados a radioterapia em pacientes que recebem ou irradiação de corpo total, dose alta única ao abdômen, ou frações diárias ao abdômen por até 24 horas após a dosagem
WO2012024583A3 (fr) Composés oxystérol
JP2011504921A5 (fr)
WO2014102776A3 (fr) Procédé de production à grande échelle de cellules de fruits et traitement de maladies au moyen desdites cellules
WO2012064159A3 (fr) Composition anticancéreuse
JP2017538693A5 (fr)
WO2018093237A3 (fr) Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité
Sulaberidze et al. Dietary fiber's benefit for gallstone disease prevention during rapid weight loss in obese patients
WO2016008642A3 (fr) Compositions comprenant du cinnamaldéhyde et du zinc et procédés d'utilisation de ces compositions
WO2018230931A3 (fr) Composition pour prévenir et traiter les maladies métaboliques
WO2012105816A3 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
NZ613264A (en) Use of vitamin k for weight maintenance and weight control
WO2012091425A3 (fr) Composition contenant, comme principe actif, un analogue de 4-hydroxytamoxifène ou un sel pharmaceutiquement acceptable de celui-ci, destinée à la prévention ou au traitement des maladies associées au syndrome métabolique
WO2012154009A3 (fr) Dérivés de thiénopyrimidine, leurs sels pharmaceutiquement acceptables, procédé de préparation de dérivés de thiénopyrimidine, et composition pharmaceutique contenant des dérivés de thiénopyrimidine en tant que principes actifs dans la prévention ou le traitement de maladies liées au diabète

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180017514.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766193

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2013503700

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766193

Country of ref document: EP

Kind code of ref document: A2